PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31478469-0	2019	Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients.	dolutegravir	132-144	CD14 molecule	Homo sapiens	16-20	
34120186-0	2021	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.	dolutegravir	30-42	CD14 molecule	Homo sapiens	61-65	
34120186-5	2021	Soluble CD14 (-11%, P < 0.001) and adiponectin (-11%, P < 0.001) significantly declined and high-sensitive C-reactive protein (-13%, P = 0.069) and oxidized LDL (-13%, P = 0.084) tended to decrease with dolutegravir.	dolutegravir	203-215	CD14 molecule	Homo sapiens	8-12	
34120186-6	2021	Switching to dolutegravir remained significantly associated with soluble CD14 and adiponectin reductions after adjustment for baseline variables.	dolutegravir	13-25	CD14 molecule	Homo sapiens	73-77	
34120186-8	2021	CONCLUSIONS: Switching from boosted PIs to dolutegravir in PLWH with high cardiovascular risk led to soluble CD14 and adiponectin reductions at 48 weeks.	dolutegravir	43-55	CD14 molecule	Homo sapiens	109-113	
35551149-7	2022	RESULTS: Through Week 48, changes in biomarkers did not significantly differ between dolutegravir + rilpivirine and CAR groups, except for increases in soluble CD14 and decreases in fatty acid binding protein-2, which favored dolutegravir + rilpivirine.	dolutegravir	85-97	CD14 molecule	Homo sapiens	160-164